BioNexus Gene Lab Corp Annual Deferred Income Tax Expense (Benefit) in USD from 2019 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
BioNexus Gene Lab Corp quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2019 to 2022.
  • BioNexus Gene Lab Corp Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $16K, a 886% increase year-over-year.
  • BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2022 was -$3.9K, a 85.4% increase from 2021.
  • BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2021 was -$26.7K, a 2260% decline from 2020.
  • BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2020 was $1.24K, a 72.3% decline from 2019.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$3.9K +$22.8K +85.4% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-31
2021 -$26.7K -$28K -2260% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 $1.24K -$3.24K -72.3% Jan 1, 2020 Dec 31, 2020 10-K 2022-04-06
2019 $4.48K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.